Aclaris Therapeutics, Inc. (ACRS Quick QuoteACRS - Free Report) announced positive results from a phase II study (WART-201) on A-101 Topical solution (A-101) for the treatment of common warts (verruca vulgaris).

The study evaluated the safety and dose-response of two concentrations of the A-101 Topical solution (40% and 45%), in comparison with placebo (vehicle).

Results from the study revealed that patients treated with the 45% formulation demonstrated a statistically significant change in Physician’s Wart Assessment (PWA) score, as well as complete clearance of the target wart after one week of treatment, compared to placebo. Moreover, the candidate was well tolerated, with local skin reactions being mostly mild in severity and similar to the placebo arm.

As per the company’s press release, about 1.9 million people are diagnosed with common warts on an annual basis.

Apart from common warts, Aclaris is also evaluating A-101 in two phase III pivotal studies and a phase III open-label safety study for the treatment of seborrheic keratosis. Aclaris expects to report initial results in the fourth quarter of 2016. Thereafter, the company plans to submit a New Drug Application in the U.S. in the first quarter of 2017 and a Marketing Authorization Application in the EU in mid 2017, assuming positive results.

ACLARIS THERAPT Price

 

ACLARIS THERAPT Price | ACLARIS THERAPT Quote

We expect investors to remain focus on further pipeline updates from the company, going forward.

Aclaris currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN Quick QuoteGERN - Free Report) , Anika Therapeutics Inc. (ANIK Quick QuoteANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP Quick QuoteANIP - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>